Home >> Private Equity >>

Exclusive: Top PE firms eye ChrysCapital’s stake in Intas Pharma

Several private equity investors are in the fray for PE firm ChrysCapital Investment Advisors Pvt. Ltd’s stake in Intas Pharmaceuticals Ltd, three persons familiar with the development told VCCircle. Intas is better known for striking the second-biggest overseas acquisition ever by an Indian drugmaker when it bought Actavis Generics’ assets in the UK and Ireland from Teva Pharmaceutical Industries Ltd for about $769 million in October last year. ChrysCapital’s planned stake sale comes almost two-and-a-half years after it partially exited the Ahmedabad-based drugmaker by selling a 10.14% stake to Singapore’s Temasek in a secondary transaction after Intas shelved its listing...

To Read the Full Story, Login
Subscribe Now &
Save up to 46%
on a 3-year subscription

Intas Pharmaceuticals Ltd. is a pharmaceutical company. Its products include tablets, capsules, parenteral and cytotoxic formulations for central nervous system (CNS), cardiovascular, diabetology, gastroenterology, urology, pain management, animal health care, oncology and biotechnology. The firm also provides contract research services, contract manufacturing services for oral solids, injectables, cytotoxic and patent dosage forms. The company was founded in 1976 and is based in Ahmadabad, Gujarat.


Upcoming Events